KSQ Therapeutics, Inc., a clinical-stage biotechnology company developing cancer therapies using its CRISPRomics discovery platform, has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279. KSQ-4279 is a first-in-class, potent, and selective small molecule inhibitor of USP1, a protein that regulates DNA damage response (DDR) in a manner distinct from other approaches, including PARP inhibitors. The molecule is currently...